WT1 promotes invasion of NSCLC via suppression of CDH1

Journal of Thoracic Oncology

Volumn 8, Issue 9, 2013, Pages 1163-1169

  Wu, Chen ^a   Zhu, Weiyou ^a   Qian, Jing ^a   He, Shaohua ^a   Wu, Changping ^b   Chen, Yijiang ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

CDH1; Invasion; Metastasis; Non small cell lung cancer; WT1

Indexed keywords

UVOMORULIN; WT1 PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION; WOUND HEALING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; WOUND HEALING; WT1 PROTEINS;

EID: 84883350639     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31829f6a5f     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Kuang P, Zhou C, Li X, et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. Lung Cancer 2012;77:427-432.
3. Rosser CJ, Goodison S. CD24, a promising biomarker in NSCLC. Biomark Med 2010;4:495.
4. Tsao AS, Liu S, Lee JJ, et al. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 2012;7:1645-1652.
5. Bradbury PA, Shepherd FA. Chemotherapy and surgery for operable NSCLC. Lancet 2007;369:1903-1904.
6. Tsao AS, Roth JA, Herbst RS. Surgery: future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol 2010;7:10-12.
7. van Meerbeeck JP. The controversial role of surgery in stage III NSCLC. Lancet Oncol 2008;9:607-608.
8. Dubey S, Schiller JH. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 2005;10:282-291.
9. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006;11:274-284.
10. Sanchez de Cos J, Sojo Gonzalez MA, Montero MV, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 2009;63:140-145.
11. Furák J, Troján I, Szöke T, et al. Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 2005;79:241-7; discussion 241.
12. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520.
13. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273:141-161.
14. Bruening W, Moffett P, Chia S, Heinrich G, Pelletier J. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett 1996;393:41-47.
15. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991;88:9618-9622.
16. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17.
17. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990;61:1257-1269.
18. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-1704.
19. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-2137.
20. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-2121.
21. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 2005;24:1648-1652.
22. Oji Y, Miyoshi Y, Kiyotoh E, et al. Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol 2004;34:74-77.
23. Menssen HD, Bertelmann E, Bartelt S, et al. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 2000;126:226-232.
24. Oji Y, Miyoshi S, Takahashi E, et al. Absence of mutations in the Wilms' tumor gene wt1 in de novo non-small cell lung cancers. Neoplasma 2004;51:17-20.
25. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011;11:111-121.
26. Martínez-Estrada OM, Lettice LA, Essafi A, et al. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet 2010;42:89-93.
27. Ward JH. NCCN Guidelines and the International Community. J Natl Compr Canc Netw 2011;9:133-134.
28. Sitaram RT, Degerman S, Ljungberg B, et al. Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 2010;103:1255-1262.
29. Johnston MR. The limits of surgical resection alone for non-small cell lung cancer. Lung Cancer 1997;17(Suppl 1):S99-102.
30. Van Schil PE. Surgery for non-small cell lung cancer. Lung Cancer 2001;34(Suppl 2):S127-S132.
31. Ye J, Wu D, Shen J, et al. Enrichment of colorectal cancer stem cells through epithelial-mesenchymal transition via CDH1 knockdown. Mol Med Rep 2012;6:507-512.
32. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012;22:725-736.
33. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 2010;285:14042-14051.
34. Yang MH, Chang SY, Chiou SH, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007;26:1459-1467.
35. Zhang H, Meng F, Liu G, et al. Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res 2011;71:1292-1301.
36. Thompson EW, Williams ED. EMT and MET in carcinoma-clinical observations, regulatory pathways and new models. Clin Exp Metastasis 2008;25:591-592.
37. Chen J, Han Q, Pei D. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol 2012;4:66-69.
38. Miller-Hodges E, Hohenstein P. WT1 in disease: shifting the epithelialmesenchymal balance. J Pathol 2012;226:229-240.
39. Geiger B, Ayalon O. Cadherins. Annu Rev Cell Biol 1992;8:307-332.
40. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-811.
41. Pinheiro H, Carvalho J, Oliveira P, et al. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Hum Mol Genet 2012;21:4253-4269.
42. Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972;48:313-324.